About: http://data.cimple.eu/news-article/c6da50dde5cbcc9ddb1fef08a196aa8aff8739006c1e2ccd7fd06678     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • British pharmaceuticals group AstraZeneca, which is finalising a vaccine against Covid-19, said Saturday it was buying US biotech firm Alexion for $39 billion to boost its work on immunology. "Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases," AstraZeneca chief executive Pascal Soriot said in a statement, announcing the year's biggest deal in the pharma sector. "We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients," he said. Both boards have agreed to the cash-and-stock deal, which values Alexion at $175 a share, a premium of 45 percent to the Boston-based company's closing price on Friday. Since taking the helm at AstraZeneca in 2012, Soriot has pushed the group into lucrative treatments such as cancer therapies, and the Alexion takeover will give it more heft in areas such as treating blood disorders. Along with researchers from the University of Oxford, AstraZeneca has developed an effective Covid-19 vaccine which the UK government plans to use as the lynchpin of its inoculation drive, after first rolling out another vaccine by Pfizer/BioNTech. But approval of the AstraZeneca/Oxford drug has been held up after queries over its initial trial results. On Tuesday, the UK partners became the first Covid-19 vaccine makers to publish final-stage clinical trial data in a scientific journal, clearing a key hurdle. The new acquisition is expected to close in the third quarter of 2021, and Alexion shareholders will own 15 percent of the combined company. "This transaction marks the start of an exciting new chapter for Alexion," Alexion chief executive Ludwig Hantson said. "We bring to AstraZeneca a strong portfolio, innovative rare disease pipeline, a talented global workforce and strong manufacturing capabilities in biologics," he said. jit/wai
schema:headline
  • UK's AstraZeneca says buying US biotech firm Alexion for $39 billion
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software